Denosumab and Male Infertility: a Prospective Intervention Study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Change in sperm production
研究概览
简要总结
The receptor activator of NF-kB ligand (RANKL) system is considered important for bone homeostasis and comprises three important factors. RANKL exist in three isoforms but the predominant function is mediated by the transmembrane ligand that binds to a specific receptor (receptor activator of NF-KB (RANK)) on a neighbour cell that subsequently activates NFKB and regulates cell cycle OPG is an endogenous secreted protein that binds RANKL and inhibits its signalling.
Thus, the RANK/RANKL system is vital for activation of the bone resorbing cells (osteoclasts). In bone the bone synthesizing cells (osteoblasts) express RANKL that signals to RANK on the immature osteoclasts. This induces proliferation and activation of the cells they start to proliferate and resorp bone. OPG is produced by somatic cells in the bone and this production is regulated by sex hormones, TGF-B and various other substances. Today a human made recombinant antibody against RANKL, Denosumab is used to treat osteoporosis as it inhibits RANKL signalling and thus causes less bone resorption in humans.
RANKL, RANK and OPG are expressed in the testis and this pathway appears to be a novel regulator of germ cell proliferation. Decreased semen quality is a major factor of male infertility. Semen quality is a measure of the ability of the sperm to accomplish fertilization. Evaluation of male fertility potential is today basically conducted through semen analysis. There is no treatment for men with no sperm in the ejaculate and there exist no drug that can increase sperm counts.Therefore, drugs that can lower RANKL expression/activity for instance an antibody against RANKL such as Denosumab may be used for this new indication: A new treatment option of infertile men with impaired semen quality.
详细描述
The receptor activator of NF-kB ligand (RANKL) system is considered important for bone homeostasis . RANKL exist in three isoforms and the effects of all isoforms are mediated through binding to a specific receptor (receptor activator of NF-KB (RANK)). RANKL is predominantly found as a transmembrane protein and signalling is therefore dependent on cell-cell interaction to a neighbouring cell expressing RANK that subsequently activates NFKB and regulates cellular activation through regulation of cell cycle i.e proliferation, differentiation and apoptosis. RANKL-RANK interaction is modified by osteoprotegerin (OPG), which is an endogenous secreted protein that binds RANKL and inhibits its signalling.
RANK/RANKL triggers a network of TRAF-mediated kinase cascades that promote osteoclast differentiation. RANKL is expressed on osteoblast cells and its receptor, Rank, on pre- osteoclastic cells. RANKL expression is stimulated by a number of factors, such as IL-1 , IL-6, IL-11 , IL-17, TNF- α, vitamin D, Ca2+, parathyroid, glucocorticoids, prostaglandin E2, and immunosuppressive drugs, and is down-regulated by TGF-α. The RANK/RANKL interaction induces differentiation and formation of multinucleated mature osteoclasts, causing bone resorption. The third protein agonist, osteoprotegerin (OPG), is also produced by osteoblasts and is known to exert an inhibitory effect on the pre-osteoclastic differentiation process. By binding to RANKL also known as osteoprotegerin binding protein (OPGbp), OPG inhibits the RANK/RANKL interaction and subsequent osteoclastogenesis. OPG is thus a very efficient anti-resorptive agent. It also serves as a decoy receptor for the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and increases cell survival by blocking the apoptotic effects of this ligand. The fact that the overexpression of OPG in mice results in severe osteopetrosis and that OPG-null mice are osteoporotic is testimony to the physiological importance of OPG. The lack of RANK or RANKL induces osteopetrosis in mice.
Thus, the RANK/RANKL system is vital for activation of the bone resorping cells (osteoclasts). In the skeleton the bone synthesizing cells (osteoblasts) express RANKL that signals to RANK on the immature osteoclasts. This induces proliferation and activation of the cells they start to proliferate and resorp bone. OPG is produced by somatic cells in the bone and this production is regulated by sex hormones, TGF-B and various other substances. Today a human made recombinant antibody against RANKL, Denosumab is used to treat osteoporosis as it inhibits RANKL signalling and causes less bone resorption in humans. RANKL signalling has only two other known additional functions in healthy humans where it is involved in lactation and the immune response.
The investigators have data showing that RANKL, RANK and OPG are expressed at both RNA and protein level in the human testis. The Sertoli cells express RANKL, while the germ cells express RANK and the peritubular cells express OPG. Normally, RANKL activates NFKB and activation of this pathway in the male gonad appears to regulate whether the testicular cells proliferate or undergo apoptosis in the testis. The investigators' in vitro, ex vivo and in vivo data from functional models support this suggestion and this pathway appears therefore to be a novel regulator of germ cell proliferation.
Decreased semen quality is a major factor of male infertility. Semen quality is an indirect measure of the ability of the sperm to accomplish fertilization. Evaluation of male fertility potential is evaluated by semen analysis. Semen analysis evaluates certain characteristics and the most common variables measured to evaluate sperm quality are: sperm count, motility and morphology.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male with an age > 18 years old
- •Referred for male infertility with sperm concentration >= 0.1 million/ml.
- •Additionally, all men must have either sperm concentration < 20 million/ml or < 50% progressive motile spermatozoa or < 12% morphological normal spermatozoa using strict criteria
排除标准
- •Men with chronic diseases such as
- •diabetes mellitus
- •Thyroid disease
- •endocrine disturbances in need of treatment
- •malignant disease
- •or diseases known to interfere with calcium homeostasis (such as inflammatory disease with granuloma: sarcoidoses, tuberculosis, Wegeners, vasculitis, inflammatory bowel disease (Crohn's and colitis ulcerosa etc).
- •Men with previous testis cancer
- •If there is an indication for testis biopsy and it is planned or conducted within the next 6 months
- •Serum 25-hydroxy-D3 < 50 nmol/l
- •Serum Calcium ion < 1,18 or > 1,35 mmol/l
- •Serum OPG >4 pg/ml
- •Serum PTH <1.6 or >6 pmol/l
- •Inhibin-B < 50 pg/ml
- •Latex Allergy
- •no good oral condition or major implants
- •BMD < -1,5 in columna lumbalis and collum femoris
- •Criteria for drop out:
- •Abrogation of the treatment
- •Newly diagnosed endocrine, calcium metabolic disease, parathyroid, thyroid, diabetes or other endocrine disease in need of treatment
- •New malignant disease
- •Treatment with chemotherapy, immunomodulating therapy, salazopyrin
- •Oral or iv treatment with steroid hormones
- •New treatment with diuretics, antihypertensive treatment, treatment the heart, calcium channel blockers
- •If testis biopsy is performed or other surgery in the genital region during the trial
- •Prolia Intoxication
研究组 & 干预措施
intervention
Denosumab (Prolia) 60 mg s.c.
干预措施: Denosumab (Drug)
结局指标
主要结局
Change in sperm production
时间窗: after 5, 20, 40, 80, 120, 180 days
evaluated by determining total sperm count and sperm concentration
次要结局
- change i serum PTH, alkaline phosphatase, calcium, phosphate,(after 5, 20, 40, 80, 120, 180 days)
- change in sperm DNA fragmentation index(after 20 and 120 days)
- change in Inhibin B(after 5, 20, 40, 80, 120, 180 days)
- change in the number of spermatozoa expressing CYP24A1, VDR or RANKL(after 5, 20, 40, 80, 120, 180 days)
- change in seminal plasma levels of pH,HCO3, calcium, zink, phosphat, FGF23, Klotho, osteocalcin, osteopontin.(after 5, 20, 40, 80, 120, 180 days)
- change in sperm motility(after 5, 20, 40, 80, 120, 180 days)
- change in semen volume(after 5, 20, 40, 80, 120, 180 days)
- change in sex hormones or gonadotropins(after 5, 20, 40, 80, 120, 180 days)
- change in BMD(after180 days)
- change i serum FGF23, Klotho, osteocalcin, osteopontin, calcitonin, pnp, procollagen III, OPG, RANKL, Sclerostin and other bone markers(after 5, 20, 40, 80, 120, 180 days)
- change in seminal plasma levels of FGF23, Klotho, osteocalcin, osteopontin.(after 5, 20, 40, 80, 120, 180 days)
- change in number of motile sperm(after 5, 20, 40, 80, 120, 180 days)
- change in number of morphological normal sperm(after 5, 20, 40, 80, 120, 180 days)
- change in semen morphology(after 5, 20, 40, 80, 120, 180 days)
- change in seminal plasma concentrations of RANKL, OPG, RANK(after 5, 20, 40, 80, 120, 180 days)
- change in bloodpressure.(after 180 days)
- Change in vitamin d metabolites(after 5, 20, 40, 80, 120, 180 days)
研究者
Martin Blomberg Jensen
Senior Researcher
Rigshospitalet, Denmark
